Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants-Reference-Cited by-同舟云学术

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants

Published:2021-08 Issue:8 Volume:4 Page:2100099
ISSN:2366-3987
Container-title:Advanced Therapeutics
language:en
Short-container-title:Adv. Therap.

Author:

Zupancic Jennifer M.¹²,Schardt John S.¹²³,Desai Alec A.¹²^ORCID,Makowski Emily K.²³,Smith Matthew D.¹²,Pornnoppadol Ghasidit²³,Garcia de Mattos Barbosa Mayara⁴,Cascalho Marilia⁴⁵,Lanigan Thomas M.⁶,Tessier Peter M.¹²³⁷^ORCID

Affiliation:

1. Department of Chemical Engineering University of Michigan Ann Arbor MI 48109 USA

2. Biointerfaces Institute University of Michigan Ann Arbor MI 48109 USA

3. Department of Pharmaceutical Sciences University of Michigan Ann Arbor MI 48109 USA

4. Department of Surgery University of Michigan Ann Arbor MI 48109 USA

5. Department of Microbiology and Immunology University of Michigan Ann Arbor MI 48109 USA

6. Division of Rheumatology Department of Internal Medicine University of Michigan Medical School Ann Arbor MI 48109 USA

7. Department of Biomedical Engineering University of Michigan Ann Arbor MI 48109 USA

Funder

National Institutes of Health

National Science Foundation

Michigan Institute for Clinical and Health Research

Publisher

Wiley

Subject

Pharmacology (medical),Biochemistry, medical,Genetics(clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adtp.202100099

Reference51 articles.

1. WHO Coronavirus (COVID‐19) Dashboard With Vaccination Data.https://covid19.who.int/(accessed: April 2021).

2. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

3. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

4. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

5. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-vivo Polyvalent Aptamer@Protein-Based Nanocarrier with Synergistic Charge Effect for High Drug Loading, High Nuclease Resistance, and High Receptor Accessibility;CCS Chemistry;2024-07-26

2. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD;Antiviral Research;2024-06

3. Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons;World Journal of Microbiology and Biotechnology;2024-05-21

4. Next generation single-domain antibodies against respiratory zoonotic RNA viruses;Frontiers in Molecular Biosciences;2024-05-09

5. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1;Vaccines;2024-04-15